"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.
Maneesh R. Jain, MD
Advertisement
Articles by Maneesh R. Jain, MD
Advertisement
Latest Updated Articles
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecanPublished: December 4th 2024 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
Ronney Abaza, MD, discusses the next wave of advancements in robotic surgery
2
Urologist describes early experience with gemcitabine intravesical system in NMIBC
3
Martin M. Miner, MD, outlines data on testosterone therapy
4
LUGPA25: Martin M. Miner, MD, recaps findings from TRAVERSE, T4DM studies
5
